Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.

@article{Asbury1998AmonafideIP,
  title={Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.},
  author={Robert F. Asbury and John A. Blessing and Richard Buller and John H. Malfetano and Jacqueline Walker and Bernd Uwe Sevin},
  journal={American journal of clinical oncology},
  year={1998},
  volume={21 2},
  pages={
          145-6
        }
}
Twenty-six evaluable patients who had leiomyosarcoma of the uterus were treated with amonafide, 300 mg/m2, for 5 consecutive days every 3 weeks. One partial response (4%) resulted. Hematologic toxicity was substantial, with grade 3 or 4 events occurring as follows: leukopenia, 12 patients (46%); thrombocytopenia, 4 patients (15%); and granulocytopenia, 7 patients (27%). One patient had transient grade 4 renal failure. Considering the poor activity and substantial toxicity that was observed, no… CONTINUE READING